NextGen Scientific LLC has issued an updated announcement to correct inaccurate information in a previously distributed press release regarding the structure and use of proceeds from its current capital raise. The company is raising $10 million from accredited investors through a Regulation D, Rule 506(c) private placement offering. Proceeds will be used to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences.
The capital will primarily support clinical and preclinical programs for two drug candidates developed by Genzada Pharmaceuticals USA, an early-stage biotechnology company focused on oncology. GZ17-6.02, an oral compound, has demonstrated safety and efficacy in preclinical and clinical studies and is currently being evaluated in a metastatic prostate cancer study at Virginia Commonwealth University. According to the company's Chief Operating Officer Cameron West, MD, FAAD, promising biological effects against a broad array of cancer types were observed during Phase I dose escalation studies for GZ17-6.02.
GZ21T, a topical therapy for cancerous and precancerous skin conditions, is expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial in actinic keratosis patients in Sweden and the Netherlands. West expressed optimism about GZ21T's potential based on preclinical data and preliminary safety profiles, suggesting it could deliver significant results in various dermatologic conditions. Proceeds will support clinical studies of GZ21T in atopic dermatitis and pre-clinical advancement, along with the clinical and pre-clinical development of GZ17-6.02 for prostate and breast cancer.
Investors in the offering gain exposure to both clinical-stage drug development and Hyatt Life Sciences, a revenue-generating nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements. Hyatt integrates traditional botanical knowledge with modern scientific validation and operates within the rapidly expanding global nutraceuticals market. The capital will also fund drug manufacturing activities and targeted marketing initiatives for the company's supplement portfolio.
NextGen Scientific positions itself as a life sciences company focused on advancing oncology and dermatology drug development while participating in the commercialization of science-backed wellness products. Through its strategic investment in Ionics Life Sciences and its subsidiaries, NextGen is building a diversified healthcare platform designed to generate long-term value through clinical innovation and active revenue streams. The company provides additional information through its investor website at https://investinnextgen.com/ and includes regulatory disclaimers at https://investinnextgen.com/disclaimers/.
This capital raise represents a significant step in funding potentially transformative cancer and dermatology treatments while supporting an established nutraceutical business. The dual focus on high-risk, high-reward drug development and stable revenue generation from supplements creates a balanced investment approach in the healthcare sector. For patients, successful development of GZ17-6.02 could offer new treatment options for metastatic prostate and breast cancers, while GZ21T might provide novel therapies for various skin conditions. The pharmaceutical industry will watch these clinical developments closely, as successful outcomes could validate new approaches to cancer and dermatology treatment.
